Clinical Trial Search

Primary: Harvey Bradshaw Index — 3.7; 3.2; 4.2 units on a scale

Primary: Glycemia — 7.1; 7.6 percent of glycosylated hemoglobin

Primary: Accuracy (FTF Decision on Patient Disposition vs. V-visit Decision on Patient Disposition) — 89 percentage of agreement

Primary: PSQ-18 General Satisfaction — 4.0; 4.5 score on a scale

Primary: Patient Clinical Experience — 1.2; 1.3 units on a scale — p=<0.05

Primary: Preventable Emergency Department (ED) Admissions — 0.038; 0.048 count of ED admissions per person per q — p=0.0793

Primary: Number of Participants With Hospital Readmission at 6 Months — 13; 48 Participants

Primary: State-Trait Anger Inventory (STAXI-2) Anger Expression Index — 56.7; 55.0 units on a scale

Primary: Change From Baseline in Insomnia Severity Index Score — 6.68; 5.13 units on a scale — p=0.138

Primary: Specialty Consultation — 66 days

Primary: Thirty-day Postoperative Mortality — 899; 866 Participants — p=0.41

Primary: Emergency Department Use — 0.1050; 0.0885 Emergency dept use rate per person-month — p=0.017

Primary: A1c — 10.1; 9.32; 8.82; 8.36 percentage of Hb that is glycosylated

Primary: Assess the Utility of Telemedicine for Follow-up Care in a Headache Medicine Practice — 87; 92.7 percentage of scheduled appointments

Primary: Agreement in Assessment of Respiratory Distress — 0.83 proportion agreement

Primary: Physician Follow up — 150; 144; 97; 99 Participants — p=0.7399

Primary: Feasibility of Conducting a Future Randomized Clinical Trial Comparing Telehealth and in Person Visits (i.e., Rate of Accrual) — 2.4 participants accrued per month

Primary: Assignment Adherence — 4; 76 Participants

Primary: Difference in Time to PACU Discharge Determination From Observation to Interaction Phase — 84.5; 91.5 Minutes

Primary: Hemoglobin A1c — 8.58; 9.19 % HbA1c — p=0.02

Primary: Time to Initiation of Therapeutic Hypothermia — 4.5 hours

Primary: Frequency of In-person Health Care Encounters — 24; 19; 41; 46 days

Primary: Number of Symptom-Free Days in the Prior 2 Weeks — 9.5; 10.1 days

Primary: Phobia Symptom Severity — 2.80; 3.18; 1.51; 1.55 units on a scale

Primary: Number of Subjects With a Significant Change in D. Pteronyssinus Levels at End of Study Evaluation — 0; 0 Participants

Primary: At Least a 50% Improvement From Baseline to Post-treatment on the Geriatric Depression Scale (GDS) — 17.6; 22.4; 22.0; 20.2 % participants with treatment response

Primary: Number of Participants Who Agree to Participate in the Study — 66; 64 participants

Primary: Average Number of Days Without Asthma Symptoms (Symptom Free Days) — 11.6; 10.97 Days — p=<0.05

Primary: Skindex-16 Change Scores Between Baseline to Month 9 - Composite Score — -12.0; -13.2 units on a scale — p=0.66

Primary: Patient Preoperative Preparedness — 63.0; 62.5 units on a scale